340B Reform: US House Bills Mark The End Of The Beginning
Energy & Commerce Health Subcommittee releases several discussion drafts at hearing on 340B drug discount program reform as the debate seems poised to move into the next phase.
You may also be interested in...
Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.
AstraZeneca, Merck & Co., Sanofi and Novartis join Eli Lilly in taking action. But providers in the US federal discount program are pushing back.
Distribution limits for Cialis prompts concerns among 340B-eligible providers that Lilly will impose similar restrictions for additional products and that other manufacturers may follow suit.